GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
T

Tissue Repair TRP.AX · AUD

Health Care · ASX · 🇦🇺 Australia

Compare

0.14

—

Close of 9 Nov 2026, in AUD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Tissue Repair

Its shares trade on ASX under the ticker TRP.AX. It has been listed since 18 November 2021. In the fiscal year to 30 June 2026, it reported revenue of A$559,702 and a net loss of A$5.4m. At that date it held total assets of A$10.3m and shareholders' equity of A$8.8m.

Tissue Repair Ltd. is a clinical stage bio pharmaceutical company. The company is headquartered in Sydney, New South Wales. The company went IPO on 2021-11-18. The firm is engaged in developing advanced wound healing products for chronic wounds and the aftercare of cosmetic procedures, with the potential for further development of related technologies. The firm is in the final stages of completing its Phase II program for its chronic wound product, TR-987. The company also concluded Phase IIB trials on its proprietary molecule, Glucoprime. The firm is also focused on commercialization of its cosmeceutical post-procedure gel product, TR Pro+, which is used in certain minimally invasive cosmetic procedures.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
18 Nov 2021

Leadership

Pay as last reported

  • Mr. Tony ChararaChief Executive Officer, Co-Founder, Executive Director, since 2024A$329,141
  • Mr. Dion CohenChief Financial Officer
  • Dr. Darryl ReedChief Operating Officer
  • Mr. William BostVice President - Manufacturing
  • Dr. Pramod NednoorVice President - Chemistry and Controls
  • Mr. Mark WaringVice President - Clinical and Regulatory Affairs
  • Ms. Sushma KejriwalCompany Secretary
  • Mr. Patryk KaniaNon-Executive Director
  • Mr. Alistair MckeoughNon-Executive Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Tissue Repair Ltd. has completed Phase II trials for TR-987, a chronic wound healing product.
  • TR Pro+ cosmeceutical gel is commercially available for post-procedure care.
  • The company's Glucoprime molecule has successfully completed Phase IIB trials.

Weaknesses

  • The company is still in clinical development stages for its main products.
  • Tissue Repair Ltd. has no products approved for market use yet.
  • The firm's focus on chronic wound healing limits its immediate revenue streams.

Opportunities

  • The global wound care market is projected to grow significantly by 2030.
  • Tissue Repair Ltd. can expand its cosmeceutical product line with TR Pro+.
  • The company can leverage its Phase II success to attract further investment.

Threats

  • Competition in the wound care market may intensify as more companies enter.
  • Regulatory approval delays could impact the commercialization timeline.
  • The biotechnology sector faces high R&D costs and funding challenges.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.